Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
A series of arylaminobenzimidazoles was designed and synthesized as Raf kinase inhibitors. Exploration of the structure-activity relationship resulted in compounds that are potent in vitro and show desirable in vivo properties.